Zimmer Partners LP Boosts Holdings in Evolus, Inc. (NASDAQ:EOLS)

Zimmer Partners LP increased its holdings in Evolus, Inc. (NASDAQ:EOLS) by 66.6% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 416,500 shares of the company’s stock after buying an additional 166,500 shares during the quarter. Zimmer Partners LP owned about 0.66% of Evolus worth $4,598,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. KBC Group NV bought a new stake in Evolus in the 4th quarter worth about $49,000. IFP Advisors Inc increased its holdings in Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after buying an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Evolus in the 4th quarter worth about $106,000. Rafferty Asset Management LLC bought a new stake in shares of Evolus during the 4th quarter valued at about $115,000. Finally, Quantbot Technologies LP bought a new stake in shares of Evolus during the 4th quarter valued at about $118,000. 90.69% of the stock is currently owned by institutional investors.

Evolus Trading Up 2.1%

Shares of NASDAQ:EOLS opened at $9.90 on Tuesday. The stock has a 50 day moving average of $11.25 and a 200 day moving average of $12.26. The company has a market cap of $638.31 million, a PE ratio of -10.88 and a beta of 1.11. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82.

Insider Activity at Evolus

In related news, CFO Sandra Beaver sold 8,996 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now directly owns 173,583 shares of the company’s stock, valued at approximately $2,301,710.58. The trade was a 4.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the transaction, the chief marketing officer now directly owns 95,671 shares in the company, valued at approximately $1,268,597.46. This represents a 4.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 86,241 shares of company stock worth $1,048,666. 5.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EOLS. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. BTIG Research began coverage on Evolus in a research note on Thursday, April 17th. They set a “buy” rating and a $21.00 price target for the company. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Finally, Barclays boosted their price target on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Evolus presently has an average rating of “Buy” and an average price target of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.